ESC Heart Failure (Apr 2024)

Clinical phenotypes of cardiogenic shock survivors: insights into late host responses and long‐term outcomes

  • Sabri Soussi,
  • Mojtaba Ahmadiankalati,
  • Jacob C. Jentzer,
  • John C. Marshall,
  • Patrick R. Lawler,
  • Margaret Herridge,
  • Alexandre Mebazaa,
  • Etienne Gayat,
  • Zihang Lu,
  • Claudia C. dosSantos,
  • the French and European Outcome Registry in Intensive Care Units (FROG‐ICU) and CCCTBG trans‐trial group study for InFACT – the International Forum for Acute Care Trialists

DOI
https://doi.org/10.1002/ehf2.14596
Journal volume & issue
Vol. 11, no. 2
pp. 1242 – 1248

Abstract

Read online

Abstract Aims An elevated risk of adverse events persists for years in cardiogenic shock (CS) survivors with high mortality rate and physical/mental disability. This study aims to link clinical CS‐survivor phenotypes with distinct late host‐response patterns at intensive care unit (ICU) discharge and long‐term outcomes using model‐based clustering. Methods and results In the original prospective, observational, international French and European Outcome Registry in Intensive Care Units (FROG‐ICU) study, ICU patients with CS on admission were identified (N = 228). Among them, 173 were discharged alive from the ICU and included in the current study. Latent class analysis was applied to identify distinct CS‐survivor phenotypes at ICU discharge using 15 readily available clinical and laboratory variables. The primary endpoint was 1 year of mortality after ICU discharge. Secondary endpoints were readmission and physical/mental disability [short form‐36 questionnaire (SF‐36) score] within 1 year after ICU discharge. Two distinct phenotypes at ICU discharge were identified (A and B). Patients in Phenotype B (38%) were more anaemic and had higher circulating levels of lactate, sustained kidney injury, and persistent elevation in plasma markers of inflammation, myocardial fibrosis, and endothelial dysfunction compared with Phenotype A. They had also a higher rate of non‐ischaemic origin of CS and right ventricular dysfunction on admission. CS survivors in Phenotype B had higher 1 year of mortality compared with Phenotype A (P = 0.045, Kaplan–Meier analysis). When adjusted for traditional risk factors (i.e. age, severity of illness, and duration of ICU stay), Phenotype B was independently associated with 1 year of mortality [adjusted hazard ratio = 2.83 (95% confidence interval 1.21–6.60); P = 0.016]. There was a significantly lower physical quality of life in Phenotype B patients at 3 months (i.e. SF‐36 physical component score). Conclusions A phenotype with sustained inflammation, myocardial fibrosis, and endothelial dysfunction at ICU discharge was identified from readily available data and was independently associated with poor long‐term outcomes in CS survivors.

Keywords